Building research capacity and clinical trials in developing countries (2010)
- Authors:
- Autor USP: HOFF, PAULO MARCELO GEHM - FM
- Unidade: FM
- DOI: 10.1016/s1470-2045(10)70168-6
- Subjects: FENÓTIPOS; NEOPLASIAS (TERAPIA); CONDUTAS TERAPÊUTICAS; PROTO-ONCOGENES; PESQUISA (CONSTRUÇÃO)
- Language: Inglês
- Imprenta:
- Source:
- Título: The lancet oncology
- ISSN: 1470-2045
- Volume/Número/Paginação/Ano: v. 11, n. 8, p. 712-713, 2010
- Este periódico possui versão em assinatura (ou híbrida)
- Este artigo NÃO possui versão em acesso aberto
- Status do Acesso Aberto: closed
-
ABNT
ARAI, Roberto Jun et al. Building research capacity and clinical trials in developing countries. The lancet oncology, v. 11, n. 8, p. 712-713, 2010Tradução . . Disponível em: https://doi.org/10.1016/s1470-2045(10)70168-6. Acesso em: 10 mar. 2026. -
APA
Arai, R. J., Mano, M. S., Castro Junior, G. de, Diz, M. D. P. E., & Hoff, P. M. G. (2010). Building research capacity and clinical trials in developing countries. The lancet oncology, 11( 8), 712-713. doi:10.1016/s1470-2045(10)70168-6 -
NLM
Arai RJ, Mano MS, Castro Junior G de, Diz MDPE, Hoff PMG. Building research capacity and clinical trials in developing countries [Internet]. The lancet oncology. 2010 ; 11( 8): 712-713.[citado 2026 mar. 10 ] Available from: https://doi.org/10.1016/s1470-2045(10)70168-6 -
Vancouver
Arai RJ, Mano MS, Castro Junior G de, Diz MDPE, Hoff PMG. Building research capacity and clinical trials in developing countries [Internet]. The lancet oncology. 2010 ; 11( 8): 712-713.[citado 2026 mar. 10 ] Available from: https://doi.org/10.1016/s1470-2045(10)70168-6 - Should patients with advanced colorectal cancer and ECOG 3/4 be treated with chemotherapy?
- Primary prevention of colorectal cancer: Myth or reality?
- Drogas moleculares
- Perspectivas no cuidado dos tumores gastrointestinais
- Obesidade e câncer
- Combination of capecitabine and oxaliplatin is an effective treatment option for advanced neuroendocrine tumors
- Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer
- Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
- Lack of association between ERCC1 expression in biliary tract malignancy and response to chemotherapy
- Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
